Research and Markets: 2011 R&D Trends: Depression - Pipeline Characterized by its Depth and Diversity

DUBLIN--(BUSINESS WIRE)-- Research and Markets(http://www.researchandmarkets.com/research/9b1915/rd_trends_depres) has announced the addition of the "R&D Trends: Depression - Pipeline characterized by its depth and diversity" report to their offering.

Several drugs have progressed through the pipeline for depression in recent years, including Pristiq (desvenlafaxine; Pfizer), Oleptro (trazodone extended release; Labopharm), and Viibryd (Forest) in the US, and Valdoxan (agomelatine; Servier/Novartis) in the EU. Despite the heightened competition within the marketplace, an abundance of drugs remain in the pipeline.

Features and benefits

  • Understand key dynamics in the R&D pipeline for new depression therapies
  • Benchmark novel and existing therapies using the target product profile identified
  • Support R&D decision making by evaluating antidepressant clinical trial designs that have set a precedent
  • Evaluate the most promising new pharmacological targets in early-stage development
  • Access prediction of how the treatment landscape may change in the next 20 years

Highlights

  • There are 46 separate programs across all stages of clinical development for depression, down from 66 in 2007 with a notably high attrition of early-stage projects. Reasons for this include promising new targets failing to yield an effective antidepressant, and big players such as GlaxoSmithKline switching its research focus.
  • Although depleted, the early-stage pipeline still has the potential to change current treatment algorithms, which are dominated by monoamine reuptake inhibitors. Popular approaches include glutamate and neuropeptide receptor modulation. The future of treatment in depression is seen as the specific targeting of treatment-resistant patients.
  • Clinical trial design in depression is largely standardized. Although not required, head-to-head trials may allow for a more favorable label and explicit marketing claims. Future trials are believed to be designed for regulatory approval in patients with treatment-resistant depression, or for use as an add-on to existing therapies.

Your key questions answered

  • What are the key trends in the depression pipeline?
  • What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?
  • How will new antidepressant treatments evolve in the next 20 years?

For more information visit http://www.researchandmarkets.com/research/9b1915/rd_trends_depres

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.